Emerging Subvariants of Covid-19 Subvariant Cicada Variant, a Systemic Overview: Diagnostic and Therapeutic Challenges Navigating the High Antigenic Shift of The Covid-19 Cicada Variant

Abstract

The ongoing evolution of SARS-CoV-2 has resulted in the emergence of several subvariants that are more transmissible, immune-evasive, and exhibit varying pathogenicity. Among them, the newly discovered Cicada variant is of interest to scientists because of its enormous antigenic drift and explosive dissemination worldwide. This review presents an in-depth discussion of the etiology, mutation pattern, transmission, diagnostic issues, and treatment considerations of the Cicada variant. The variant has wide mutations in the spike protein, especially in receptor-binding regions, that aid immune evasion and reduce vaccine efficacy. The available methods of diagnosis, such as RT-PCR and antigen-based methods are limited by mutation-related target failure. Monoclonal antibodies and antiviral drugs are therapeutically questionable because their efficacy is not always the same, which poses a concern regarding treatment. Implications for public health, surveillance plans, and future research directions are also discussed in this review. The dynamic character of the Cicada variant is critical to comprehending diagnostic preparedness and maximizing therapeutic interventions to support the current COVID-19 pandemic.